Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

What You Need to Know About Quest Diagnostics' Q2 Earnings Results

By Keith Speights - Jul 23, 2019 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The laboratory services company beat Wall Street estimates despite reporting only modest revenue growth and another earnings decline.

The last time Quest Diagnostics ( DGX 1.62% ) announced its quarterly results, in April, revenue increased 0.4% compared to the prior-year period. It was a different story with earnings, though, with a year-over-year decline of 7.9%.

Quest Diagnostics announced its second-quarter results before the market opened on Tuesday. This time around, there was again both good news and bad news for investors. Here are the highlights of the company's Q2 update.

Scientist holding test tube

Image source: Getty Images.

By the numbers

Quest Diagnostics' top-line performance improved in the second quarter. Revenue rose 1.8% year over year to $1.95 billion. Analysts estimated that the company's revenue for the second quarter would come in at $1.94 billion.

The company announced generally accepted accounting principles (GAAP) net income of $1.51 per share in the second quarter. This marked a 3.9% decline from the $1.57 per share reported in the same quarter of 2018. 

Quest Diagnostics' adjusted net income in the second quarter was $1.73 per share. This was a slight decline from the company's result in the prior-year period, $1.75 per share. However, it was well above the consensus analysts' adjusted earnings estimate of $1.68 per share.

Behind the numbers

The company's revenue has been slowly but steadily climbing over the past couple of quarters. Quest Diagnostics CEO Steve Rusckowski attributed the increase to volume growth stemming from the company's expanded network access. He added that the company's "strong volume growth combined with our strategy to drive operational excellence helped offset the significant reimbursement pressures we are experiencing this year."

While revenue has been rising, Quest's earnings continue to slide. The biggest reason for the company's year-over-year earnings decline was increased income tax expense in the second quarter of 2019. Quest's operating expenses also increased compared to the prior-year period.

Looking ahead

Quest Diagnostics gained Preferred Lab Network status with UnitedHealth Group's UnitedHealthcare segment during the second quarter. Rusckowski stated that this will be a multiyear opportunity for the company that will develop over time.

The company still projects that full-year 2019 net revenue will be between $7.6 billion and $7.75 billion. This reflects year-over-year revenue growth between 1% and 3%. Quest thinks that adjusted earnings per share (EPS) will be at least $6.40, which would represent a year-over-year increase of 1.4%.

Quest obviously isn't a stock that growth-oriented investors will favor. However, its dividend yield of 2.16% looks relatively attractive. The company also continues to maintain a low payout ratio that gives it plenty of financial flexibility to keep the dividends flowing.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
$156.82 (1.62%) $2.50
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
$452.10 (1.36%) $6.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.